


## PHARMACEUTICAL 2020

## Global Blood Therapeutics Inc. Rank 134 of 362







## PHARMACEUTICAL 2020



The relative strengths and weaknesses of Global Blood Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Global Blood Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Global Blood Therapeutics Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 200% points.

The company's Economic Capital Ratio, given in the ranking table, is -88%, being 215% points above the market average of -303%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 627,997           |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 71,453            |
| Liabilities, Non-Current                    | 145,952           |
| Other Assets                                | 140,989           |
| Other Compr. Net Income                     | 802               |
| Other Expenses                              | 283,571           |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 14,697            |
| Property and Equipment                      | 27,113            |
| Research and Development                    | 0                 |
| Revenues                                    | 2,108             |
| Selling, General and Administrative Expense | 0                 |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 796,099           |
| Liabilities              | 217,405           |
| Expenses                 | 283,571           |
| Stockholders Equity      | 578,694           |
| Net Income               | -266,766          |
| Comprehensive Net Income | -266,365          |
| Economic Capital Ratio   | -88%              |